Ketolide ABT-773 is active against Toxoplasma gondii.
ABT-773 is active in vitro and in vivo against Toxoplasma gondii. It inhibited replication of RH strain tachyzoites in human foreskin fibroblasts. Mice infected intraperitoneally with tachyzoites and treated orally with 25, 50 or 100 mg/kg/day of ABT-773 for 10 days had 20% (P: = 0.016), 50% (P: = 0.003) and 100% (P: = 0.001) survival, respectively. Remarkable and highly significant survival was also noted in mice infected orally with strain C56 cysts and treated with ABT-773. Thus, ABT-773 may be useful for therapy of human toxoplasmosis.
Khan
A A
AA
Research Institute, Palo Alto Medical Foundation, Ames Building, 795 El Camino Real, Palo Alto, CA. Stanford University School of Medicine, Palo Alto, CA 94301, USA.
Araujo
F G
FG
Craft
J C
JC
Remington
J S
JS
D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004195:Disease Models, Animal; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D048628:Ketolides; D051379:Mice; D014122:Toxoplasma / Q000187:drug effects* / Q000254:growth & development; D014123:Toxoplasmosis / Q000188:drug therapy* / Q000469:parasitology
D000981:Antiprotozoal Agents; D048628:Ketolides; D004917:Erythromycin; C405499:cethromycin